Market for Drug Delivery Systems in the US
The demand for drug delivery systems in the US is visualized to grow and reach over $135 billion by come 2015, as a result of growth of almost 9% every year since 2010. The largest share is expected to be produced by oral drugs and parenteral or injectable drug delivery systems are expected to grow at a rapid speed as well, especially in cancer applications.
The fastest growth in the coming years is likely to be witnessed by implantable drug delivery systems. This segment is going to be upgraded with the latest range drugeluting stents with more sophisticated designs and reduced risks. Also to have an astounding growth will be the drug delivery systems for hormones and cardiology agents. Product development lays emphasis on introducing innovative technologies which help improve dosing and monitor patient safety real well. It includes services such as multiple dosing arrangement in a single tablet, progressive meters etc.
There's no ignoring the fact that throughout the past decade, demand for drug delivery system has only shot up, exceeding average growth momentum of the overall US pharmaceutical market. The credit for this undoubtedly goes to advanced technology and also generic contention. It has also prompted pharmaceutical corporations to accommodate widely prescribed medicines to expand their commercial exclusivity span beyond patent expiry dates of genuine ingredients. With ever improving mechanization, possibilities of massive breakthroughs in this field cannot be ruled out.
The leading producers in the US drug delivery systems market in the recent years have been Catalent Pharma Solutions, ALZA (Johnson & Johnson) and Ireland-based Elan.
In this industry scenario, Taiyou Research analyzes the Market for Drug Delivery Systems in the US. The report covers the following:
The fastest growth in the coming years is likely to be witnessed by implantable drug delivery systems. This segment is going to be upgraded with the latest range drugeluting stents with more sophisticated designs and reduced risks. Also to have an astounding growth will be the drug delivery systems for hormones and cardiology agents. Product development lays emphasis on introducing innovative technologies which help improve dosing and monitor patient safety real well. It includes services such as multiple dosing arrangement in a single tablet, progressive meters etc.
There's no ignoring the fact that throughout the past decade, demand for drug delivery system has only shot up, exceeding average growth momentum of the overall US pharmaceutical market. The credit for this undoubtedly goes to advanced technology and also generic contention. It has also prompted pharmaceutical corporations to accommodate widely prescribed medicines to expand their commercial exclusivity span beyond patent expiry dates of genuine ingredients. With ever improving mechanization, possibilities of massive breakthroughs in this field cannot be ruled out.
The leading producers in the US drug delivery systems market in the recent years have been Catalent Pharma Solutions, ALZA (Johnson & Johnson) and Ireland-based Elan.
In this industry scenario, Taiyou Research analyzes the Market for Drug Delivery Systems in the US. The report covers the following:
- A statistical analysis of the US market for drug delivery systems.
- Analysis of the demand for drug delivery systems segmented according to products. Segments for drug delivery systems analyzed include inhalation drug delivery systems, implantable and transdermal drug delivery systems, oral drug delivery systems and parenteral or injectable drug delivery systems.
- Overview of the US pharmaceutical industry, industry trade, industry trends, and the industry structure are analyzed, along with an analysis of the technological developments in the industry.
- Applications of drug delivery systems in the US analyzed in this research report include the drug delivery systems to deliver CNS agents, drug delivery systems to deliver gastrointestinal agents, drug delivery systems to deliver hormones and other agents, drug delivery systems to deliver respiratory agents, and drug delivery systems to deliver other agents.
- Major players are analyzed in this report through a company overview, analysis of business segments, presence in the market, and a SWOT analysis.
Contents
1. EXECUTIVE SUMMARY2. OVERVIEW OF DRUG DELIVERY SYSTEMS
3. MARKET FOR DRUG DELIVERY SYSTEMS IN THE US
3.1 Market Profile
3.2 Demand for Drug Delivery Systems in the US
3.3 Demand for Inhalation Drug Delivery Systems
3.4 Demand for Implantable and Transdermal Drug Delivery Systems
3.5 Demand for Oral Drug Delivery Systems
3.6 Demand for Parenteral/Injectable Drug Delivery Systems
3.7 US Pharmaceutical Industry Profile & Import/Export Scenario
4. MARKET SEGMENTATION BY APPLICATIONS
4.1 Drug Delivery Systems to Deliver Central Nervous System (CNS) Agents
4.2 Drug Delivery Systems to Deliver Gastrointestinal Agents
4.3 Drug Delivery Systems to Deliver Hormones & Other Agents
4.4 Drug Delivery Systems to Deliver Respiratory Agents
4.5 Drug Delivery Systems to Deliver Other Agents
5. TECHNOLOGICAL DEVELOPMENTS IN THE INDUSTRY
6. INDUSTRY TRENDS & INDUSTRY STRUCTURE
6.1 Trends
6.2 Industry Structure
7. MAJOR INDUSTRY PLAYERS
7.1 Catalent Pharma Solutions
7.1.1 Company Overview
7.1.2 Business Segments
7.1.3 Major Products & Services
7.1.4 Presence in the Industry
7.1.5 SWOT Analysis
7.2 Elan Corporation plc
7.2.1 Company Overview
7.2.2 Business Segments
7.2.3 Major Products & Services
7.2.4 Presence in the Industry
7.2.5 SWOT Analysis
7.3 Johnson & Johnson
7.3.1 Company Overview
7.3.2 Business Segments
7.3.3 Major Products & Services
7.3.4 Presence in the Industry
7.3.5 SWOT Analysis
7.4 Abbott Laboratories
7.4.1 Company Overview
7.4.2 Business Segments
7.4.3 Major Products & Services
7.4.4 SWOT Analysis
7.5 Amgen Inc
7.5.1 Company Overview
7.5.2 Business Segments
7.5.3 Major Products & Services
7.5.4 SWOT Analysis
7.6 AstraZeneca
7.6.1 Company Overview
7.6.2 Business Segments
7.6.3 Major Products & Services
7.6.4 SWOT Analysis
7.7 Becton Dickinson
7.7.1 Company Overview
7.7.2 Business Segments
7.7.3 Major Products & Services
7.7.4 SWOT Analysis
7.8 Eli Lilly
7.8.1 Company Overview
7.8.2 Business Segments
7.8.3 Major Products & Services
7.8.4 SWOT Analysis
7.9 GlaxoSmithKline Plc
7.9.1 Company Overview
7.9.2 Business Segments
7.9.3 Major Products & Services
7.9.4 SWOT Analysis
7.10 Merck & Company
7.10.1 Company Overview
7.10.2 Business Segments
7.10.3 Major Products & Services
7.10.4 SWOT Analysis
7.11 Novartis AG
7.11.1 Company Overview
7.11.2 Business Segments
7.11.3 Major Products & Services
7.11.4 SWOT Analysis
7.12 Pfizer
7.12.1 Company Overview
7.12.2 Business Segments
7.12.3 Major Products & Services
7.12.4 SWOT Analysis
7.13 Sanofi SA
7.13.1 Company Overview
7.13.2 Business Segments
7.13.3 Major Products & Services
7.13.4 SWOT Analysis
7.14 3M
7.14.1 Company Overview
7.14.2 Business Segments
7.14.3 Majors Products & Services
7.14.1 SWOT Analysis
8. INDUSTRY FORECAST
8.1 Market Outlook
8.2 Demand Forecast for Inhalation Drug Delivery Systems
8.3 Demand Forecast for Implantable and Transdermal Drug Delivery Systems
8.4 Demand Forecast for Oral Drug Delivery Systems
8.5 Demand Forecast for Parenteral/Injectable Drug Delivery Systems
8.6 Forecast for Drug Delivery Systems to Deliver Central Nervous System (CNS) Agents
8.7 Forecast for Drug Delivery Systems to Deliver Gastrointestinal Agents
8.8 Forecast for Drug Delivery Systems to Deliver Hormones & Other Agents
8.9 Forecast for Drug Delivery Systems to Deliver Respiratory Agents
8.10 Forecast for Drug Delivery Systems to Deliver Other Agents
9. GLOSSARY Skip to top